Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cabozantinib in Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
NCT04022343Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- Aug 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in clear cell renal cell carcinoma (ccRCC), sponsored by Emory University. Started Aug 2019; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04022343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022343.